A Beta-only IL-2 ImmunoTherapY Study

Key facts

Sponsor

Medicenna Therapeutics, Inc.

Principal Investigator

Nina Merchant

Medicenna Therapeutics

Intervention

MDNA11(drug)

Enrollment

115 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2026

Study locations (27)

• Sharp Memorial Hospital, San Diego, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
• Providence Saint John's Health Center, Santa Monica, California, United States
• Boca Raton Regional Hospital, Boca Raton, Florida, United States
• Emory - Winship Cancer Institute, Atlanta, Georgia, United States
• Karmanos Cancer Institute, Detroit, Michigan, United States
• MD Anderson Cancer Center, Houston, Texas, United States
• Scientia Clinical Research, Randwick, New South Wales, Australia
• Macquarie University, Sydney, New South Wales, Australia
• University of the Sunshine Coast, Buderim, Queensland, Australia
• Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia
• Princess Margaret Cancer Center, Toronto, Ontario, Canada
• Mater Misericordiae University Hospital, Dublin, Ireland
• START Lisbon - Centro de Ensaios Clínicos, ULS Sta Maria, Lisbon, Portugal
• Instituto Portugues De Oncologia Do Porto, Porto, Portugal
• +12 more locations on ClinicalTrials.gov

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →